Identifying vulnerability markers in prodromal patients: a step in the right direction for schizophrenia prevention.
Research has shown that many of the long-term deficits that are observable in schizophrenia populations are present prior to the emergence of psychotic symptoms. Recent research suggests schizophrenia has a "prodromal" period, whereby significant changes from premorbid functioning can be observed. Accurate classification of this period could have far-reaching implications for schizophrenia prevention. This article aims to provide an indepth evaluation of the perceived benefits of vulnerability marker research in this unique phase. It is hoped that identification of such markers may improve the predictive potency of prodromal criteria, and perhaps pave the way for future screening and primary prevention strategies.
Collaborative Therapy Unit, the Mental Health Research Institute, Parkville, Australia.
Lucy
L
Knowles
Tonmoy
T
Sharma
D014150:Antipsychotic Agents / Q000627:therapeutic use; D042241:Early Diagnosis; D006801:Humans; D011569:Psychiatric Status Rating Scales; D018570:Risk Assessment; D012559:Schizophrenia / Q000175:diagnosis* / Q000188:drug therapy; D012565:Schizophrenic Psychology; D012569:Schizotypal Personality Disorder / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology
D014150:Antipsychotic Agents